Authors

Howard Fine, MD

Latest:

Dr. Fine on Therapeutic Metabolic Targets in Brain Cancer

Howard Hochster, MD, FACP

Latest:

Dr Hochster on the Role of Cooperative Trials in Academic and Community Health Care Settings

Howard S. Hochster, MD, FACP, discusses the role of cooperative group clinical trials in bridging the gap between academic and community cancer centers.

Howard Hochster, MD, FACP, Rutgers Cancer Institute

Howard I. Scher, MD

Latest:

Dr Scher on the Importance of Molecular Testing in Prostate Cancer

Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.

Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center

Howard Jack West, MDest, MD

Latest:

E-patients: The Genie is Out of the Bottle

Melissa received a metastatic lung cancer diagnosis just a few weeks after celebrating her 40th birthday. Within hours of hearing her diagnosis from her primary care physician, she started searching the Internet about her disease and what to expect in terms of treatments.

Howard Kaufman, MD

Howard L. Kaufman, MD

Latest:

Dr. Kaufman on T-VEC in Melanoma

Howard L. Kaufman, MD, chief surgical officer, associate director for Clinical Science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses oncolytic immunotherapy talimogene laherparepvec (T-VEC; Imlygic) for treatment of patients with melanoma, as well as the agent's side effect profile.

Howard L. Kaufman, MD, FACS,

Latest:

The Search for Immune-Specific Biomarkers Is in Full Swing

An improved understanding of how the immune system recognizes and eradicates cancer cells, along with advances in drugs that effectively promote antitumor immune responses, is revolutionizing the field of cancer therapy.

Howard L. Kaufman, MD, Rutgers Cancer Institute of New Jersey

Howard Levine, PharmD, Queens Medical Associates

Howard M. Sandler, MD

Latest:

Dr. Sandler Discusses Hypofractionation in Prostate Cancer

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Howard S. Hochster, MD

Latest:

Dr. Howard S. Hochster on TAS-102 Compared to 5FU

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

Howard S. Hochster, MD, FACP

Latest:

Dr Hochster on the Importance of Clinical Trial Participation in Cancer Care

Howard S. Hochster, MD, discusses the importance of clinical trial participation for patients with cancer and highlights the use of precision medicine across the treatment armamentarium.

Howard S. Hochster, MD, FACP, Rutgers Cancer Institute of New Jersey

Howard S. Hochster, MD, Yale Cancer Center

Howard Sandler, MD, MS, FASTRO

Latest:

Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer

Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

Howard "Skip" A. Burris, III, MD

Latest:

Dr. Burris on the Exploration of PARP Inhibitors in TNBC

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Howard "Skip" Burris, III, MD

Latest:

Dr. Burris on Molecular Profiling in Breast Cancer

Howard "Skip" A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the impact of molecular profiling in breast cancer.

Howard W. Follis, MD

Latest:

EHRs in the Urology Office

The implementation of electronic health records to replace paper charts in urology practices is a recent phenomenon that is picking up some serious momentum.